Impact of SSRI Therapy on Risk of Conversion From Mild Cognitive Impairment to Alzheimer's Dementia in Individuals With Previous Depression
Impact of SSRI Therapy on Risk of Conversion From Mild Cognitive Impairment to Alzheimer's Dementia in Individuals With Previous Depression
复制标题
DOI：
10.1176/appi.ajp.2017.17040404
复制
发表时间：
2018-03-01
影响因子：
17.7
通讯作者：
Schneider, Anja
中科院分区：
文献类型：
--
作者：
Bartels, Claudia;Wagner, Michael;Schneider, Anja
目的：抑郁症与阿尔茨海默病的风险增加有关。研究表明，选择性5-羟色胺再摄取抑制剂（SSRI）西酞普兰减少淀粉样β蛋白的产生和斑块负荷。作者评估了SSRI治疗对CSF生物标志物的影响以及从轻度认知障碍（MCI）到Alzheimer's dementia的进展。方法：通过Kaplan-Meier分析以及以ApoE 4状态和年龄为协变量的方差和协方差分析，评估了来自纵向Alzheimer's Disease Neuroimaging Initiative的755名当前非抑郁参与者的数据集。在有抑郁症史的MCI患者中，与短期SSRI治疗、其他抗抑郁药治疗或未治疗以及与无抑郁症史的MCI患者相比，长期SSRI治疗（>4年）与延迟进展至阿尔茨海默氏痴呆症约3年显著相关。CSF生物标志物水平无显着差异，观察治疗groups.Conclusions：长期SSRI治疗可能会延迟进展MCI阿尔茨海默氏症。
Objective: Depression is associated with an increased risk of Alzheimer's disease. Research has shown that the selective serotonin reuptake inhibitor (SSRI) citalopram decreases amyloid-beta generation and plaque load. The authors evaluated the impact of SSRI treatment on CSF biomarkers and progression from mild cognitive impairment (MCI) to Alzheimer's dementia.Method: Data sets from 755 currently non-depressed participants from the longitudinal Alzheimer's Disease Neuroimaging Initiative were evaluated by Kaplan-Meier analysis and analyses of variance and covariance with ApoE4 status and age as covariates.Results: In MCI patients with a history of depression, longterm SSRI treatment (>4 years) was significantly associated with a delayed progression to Alzheimer's dementia by approximately 3 years, compared with short-term SSRI treatment, treatment with other antidepressants, or no treatment and compared with MCI patients without a history of depression. No differences in CSF biomarker levels were observed between treatment groups.Conclusions: Long-term SSRI treatment may delay progression from MCI to Alzheimer's dementia.